1. Emerging role of RNA interference in immune cells engineering and its therapeutic synergism in immunotherapy.
- Author
-
Monty, Masuma Akter, Islam, Md. Ariful, Nan, Xu, Tan, Jingwen, Tuhin, Israth Jahan, Tang, Xiaowen, Miao, Miao, Wu, Depei, and Yu, Lei
- Subjects
- *
IMMUNOTHERAPY , *RNA , *T cells , *CELL physiology , *THERAPEUTICS - Abstract
RNAi effectors (e.g. siRNA, shRNA and miRNA) can trigger the silencing of specific genes causing alteration of genomic functions becoming a new therapeutic area for the treatment of infectious diseases, neurodegenerative disorders and cancer. In cancer treatment, RNAi effectors showed potential immunomodulatory actions by down-regulating immuno-suppressive proteins, such as PD-1 and CTLA-4, which restrict immune cell function and present challenges in cancer immunotherapy. Therefore, compared with extracellular targeting by antibodies, RNAi-mediated cell-intrinsic disruption of inhibitory pathways in immune cells could promote an increased anti-tumour immune response. Along with non-viral vectors, DNA-based RNAi strategies might be a more promising method for immunomodulation to silence multiple inhibitory pathways in T cells than immune checkpoint blockade antibodies. Thus, in this review, we discuss diverse RNAi implementation strategies, with recent viral and non-viral mediated RNAi synergism to immunotherapy that augments the anti-tumour immunity. Finally, we provide the current progress of RNAi in clinical pipeline. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF